The FDA approves Somatuline® Depot (lanreotide) Injection Extended Dosing Interval as part of Ipsen’s Prior Approval Supplement application

This article or press release has no online content. Please download the associated documents for more information.

© Ipsen Pharma, 65 Quai Georges Gorse, 92100 Boulogne-Billancourt, France. All rights reserved. - 2019